21:18 , Feb 11, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Mesothelioma Cell and mouse studies suggest GHRH receptor antagonists could help treat malignant pleural mesothelioma (MPM). In two human-derived MPM cell lines and patient-derived MPM cells, two previously identified GHRH receptor antagonists inhibited growth...
19:55 , Nov 6, 2017 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Heart failure Cell culture and mouse studies suggest GHRH receptor agonists could help treat heart failure. In a rat cardiomyoblast cell line, primary rat ventricular myocytes and human induced pluripotent stem (iPS) cell-derived cardiomyocyte...
20:29 , Feb 3, 2017 |  BC Week In Review  |  Company News

Biscayne Pharmaceuticals deal

Biscayne Pharmaceuticals spun out CNS company Biscayne Neurotherapeutics Inc. (Miami, Fla.). The newco's sole asset is BIS-001 , which is in development to treat refractory forms of epilepsy, including partial complex seizures and Dravet syndrome....
17:36 , Feb 3, 2017 |  BC Week In Review  |  Financial News

Biscayne Neurotherapeutics completes venture financing

Neurology company Biscayne Neurotherapeutics Inc. (Miami, Fla.) raised $3 million in a series B round co-led by Quark Venture's Global Health Sciences Fund, GF Securities and Mesa Verde Venture Partners. Existing investors and new private...
17:37 , Jan 25, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Retinoblastoma In vitro studies suggest antagonizing the GHRH receptor could help treat retinoblastoma. In a human retinoblastoma cell line, GHRH receptor expression was higher than in normal eye-derived cell lines. In the retinoblastoma cell...
08:00 , Feb 11, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Growth hormone-releasing hormone (GHRH) receptor

Endocrine/metabolic disease INDICATION: Dyslipidemia Rat studies suggest GHRH receptor antagonists could help treat dyslipidemia associated with Type I diabetes. A rat model of Type I diabetes had higher GHRH receptor levels in the small intestine...
08:00 , Nov 19, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Growth hormone-releasing hormone (GHRH) receptor

Endocrine/metabolic disease INDICATION: Diabetes In vitro and mouse studies suggest GHRH receptor agonists could improve engraftment of islet cell transplant to treat diabetes. In a rat pancreatic β cell line, the GHRH receptor agonist MR-409...
08:00 , Nov 2, 2015 |  BC Week In Review  |  Company News

Biscayne Pharmaceuticals, Insero Health deal

Biscayne merged with Insero on June 30. Biscayne is developing growth hormone-releasing hormone (GHRH) receptor analogs. Biscayne’s lead compound is BIS-001, a selective acetylcholinesterace (AChE) inhibitor that has completed a Phase I trial in adults...
07:00 , Sep 8, 2014 |  BioCentury  |  Emerging Company Profile

Biscayne: Antagonizing cancer

Biscayne Pharmaceuticals Inc. is developing peptide antagonists that target three different cancer growth pathways and could provide an alternative for prostate cancer patients who have become insensitive to hormone-based therapies. The company plans to enter...
08:00 , Feb 28, 2013 |  BC Innovations  |  Targets & Mechanisms

Islet transplants find the adrenal gland

German and U.S. researchers have shown that transplantation into the adrenal gland of islet cells preconditioned with an improved peptide agonist of growth hormone-releasing hormone may help normalize glucose levels in diabetic mice better than...